Loading...
In the phase III E2100 trial, patients who received bevacizumab plus paclitaxel as first-line chemotherapy for metastatic breast cancer had significantly better response rates and longer progression-free survival (PFS) than did those who received paclitaxel alone (N Engl J Med 2007; 357:266). This trial was pivotal in earning FDA approval of bevacizumab as a treatment for metastatic breast cancer. Now, in the phase III AVADO trial, researchers enrolled 736 patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer who had not been treated with chemotherapy. Participants were randomized to docetaxel (100 mg/m2) plus placebo, docetaxel plus bevacizumab (7.5 mg/kg), or docetaxel plus bev…